Product Description
Almorexant (ACT-078573) is an orally active dual orexin receptor antagonist that is being developed by Actelion Ltd, in collaboration with GlaxoSmithKline plc, for the treatment of primary insomnia. Almorexant is a first-in-class compound that targets the orexin system, which plays a key role in wake promotion and stabilization, in addition to having other regulatory functions. Decreasing orexin activity was hypothesized to have a sleep-promoting effect. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/20047164/)
Mechanisms of Action: OX1R Antagonist,OX2R Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Midnight Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Insomnia
Phase 1: Insomnia|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AC-057-116 | P1 |
Completed |
Other |
2010-02-01 |
|
| RESTORA 1 | P3 |
Completed |
Insomnia |
2009-09-01 |
|
| AC-057A201 | P2 |
Completed |
Insomnia |
2008-04-01 |
|
| Insomnia | P1 |
Completed |
Insomnia |
2007-08-01 |